Trade

with

Stemline Therapeutics Inc
(NASDAQ: STML)
AdChoices
12.79
-0.06
-0.47%
After Hours :
12.79
0.00
0.00%

Open

12.91

Previous Close

12.85

Volume (Avg)

106.03k (157.10k)

Day's Range

12.32-13.12

52Wk Range

10.50-33.55

Market Cap.

169.57M

Dividend Rate ( Yield )

-

Beta

-

Shares Outstanding

13.26M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
  • Management effectiveness
Industry Biotechnology
Highlights
Analyst Recommendation: Buy
    • Revenue

    • 71.00k

    • Net Income

    • -24.20M

    • Market Cap.

    • 169.57M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -13,237.59

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • -

    • Forward P/E

    • -6.06

    • Price/Sales

    • 769.23

    • Price/Book Value

    • 2.54

    • Price/Cash flow

    • -6.87

      • EBITDA

      • -23.60M

      • Return on Capital %

      • -34.18

      • Return on Equity %

      • -36.12

      • Return on Assets %

      • -34.18

      • Book Value/Share

      • 5.04

      • Shares Outstanding

      • 13.26M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Buy
        • 1 Year Price Target

        • 62.00

        • Credit Rating

        • -

        • Analysts

        • 3

        • EPS Estimate

        • -2.12

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 0.00

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • -

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 100.00

            • 82.75

            • Pre-Tax Margin

            • -13,237.59

            • 39.38

            • Net Profit Margin

            • -13,237.59

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • -

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.76

              • Current Ratio

              • 5.64

              • 2.92

              • Quick Ratio

              • 5.25

              • 2.35

              • Interest Coverage

              • -2,386.43

              • 38.02

              • Leverage Ratio

              • 1.07

              • 2.21

              • Book Value/Share

              • 5.04

              • 4.75

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -5.80

                • 277.78

                • P/E Ratio 5-Year High

                • -21.35

                • 634.30

                • P/E Ratio 5-Year Low

                • -4.67

                • 124.82

                • Price/Sales Ratio

                • 769.23

                • 9.35

                • Price/Book Value

                • 2.55

                • 8.50

                • Price/Cash Flow Ratio

                • -6.87

                • 50.25

                • Key Metrics

                • Company

                  • Shares Short

                    as of -

                  • -

                  • Short Ratio

                    as of -

                  • -

                  • Short % of Float

                    as of -

                  • -

                  • Shares Short

                    prior month

                  • -

                  • Trailing Annual Dividend Yield

                  • -

                  • 5 Year Average Dividend Yield

                  • -

                  • Key Metrics

                  • Company

                    • Payout Ratio

                    • -

                    • Dividend Date

                    • -

                    • Ex-Dividend Date

                    • -

                    • Last Split Factor

                      new per old

                    • -

                    • Last Split Date

                    • -

                    • Key Metrics

                    • Company

                    • Industry

                      • Return on Equity %

                        (5-Year Average)

                      • -36.12

                        (-)

                      • 37.63

                        (27.20)

                      • Return on Assets %

                        (5-Year Average)

                      • -34.18

                        (-)

                      • 17.22

                        (13.81)

                      • Return on Capital %

                        (5-Year Average)

                      • -36.11

                        (-)

                      • 21.78

                        (17.31)

                      • Income/Employee

                      • -

                      • 117.08k

                      • Inventory Turnover

                      • -

                      • 1.48

                      • Asset Turnover

                      • 0.00

                      • 0.55

                      Current Historical
                      Financials
                      • Income Statement
                      • Balance Sheet
                      • Cash Flow
                      Operating Income
                      -23.98M
                      Operating Margin
                      -33,773.89
                      Total Equity
                      -
                      Retained Earnings
                      -
                      Free Cashflow
                      -
                      Price/Cashflow
                      -6.87
                      Ownership

                      Institutional Ownership

                      69.97%

                      Top 10 Institutions

                      53.41%

                      Mutual Fund Ownership

                      43.81%

                      Float

                      72.16%

                      5% / Insider Ownership

                      16.84%

                      Corporate insiders or major stockholders reporting trading activity in the stock.

                      Top Mutual Fund Owners

                      Top Institutional Owners

                      Mutual Fund Name

                      Institution Name

                      • Mutual Fund Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • Fidelity® Select Biotechnology Portfolio

                      •  

                        1,243,399

                      • 0.00

                      • 9.38

                      • Franklin Biotechnology Discovery

                      •  

                        808,130

                      • 70.37

                      • 6.11

                      • Eventide Gilead Fund

                      •  

                        435,500

                      • 47.68

                      • 3.28

                      • Janus Global Life Sciences Fund

                      •  

                        409,104

                      • 19.34

                      • 3.09

                      • Franklin Biotechnology Discovery Fund

                      •  

                        354,400

                      • 0.00

                      • 2.67

                      • Fidelity Advisor® Biotechnology Fund

                      •  

                        292,993

                      • 0.00

                      • 2.21

                      • Goldman Sachs Small/Mid Cap Growth Fund

                      •  

                        272,804

                      • -1.65

                      • 2.06

                      • Pru Ret Small Cap Growth/TimesSquare SP

                      •  

                        218,576

                      • -1.13

                      • 1.65

                      • AMG TimesSquare Small Cap Growth Fund

                      •  

                        204,774

                      • -1.54

                      • 1.54

                      • Vanguard Total Stock Mkt Idx

                      •  

                        179,382

                      • 0.00

                      • 1.35

                      • Institution Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • Fidelity Management and Research Company

                      •  

                        1,640,892

                      • 0.00%

                      • 12.38

                      • Franklin Advisers, Inc.

                      •  

                        1,162,530

                      • +0.88%

                      • 8.77

                      • TimesSquare Capital Management, LLC

                      •  

                        798,025

                      • -1.61%

                      • 6.02

                      • Eventide Asset Management, LLC

                      •  

                        559,800

                      • +54.47%

                      • 4.22

                      • Ridgeback Capital Investments L.p.

                      •  

                        506,699

                      • -13.13%

                      • 3.87

                      • Janus Capital Management LLC

                      •  

                        495,384

                      • +15.45%

                      • 3.74

                      • SAC Capital Advisors, LP

                      •  

                        353,000

                      • +17.59%

                      • 2.67

                      • Baker Bros Advisors LLC

                      •  

                        338,671

                      • 0.00%

                      • 2.55

                      • Goldman Sachs Asset Management, L.P.

                      •  

                        301,902

                      • +41.28%

                      • 2.28

                      Company Profile

                      Sector

                      Healthcare

                      Industry

                      Biotechnology

                      Type

                      Distressed

                      Style

                      -

                      Stemline Therapeutics Inc was incorporated under the laws of the State of Delaware on August 8, 2003. The Company is a clinical-stage biopharmaceutical company engaged in discovering, acquiring, developing and commercializing proprie...moretary therapeutics that target both cancer stem cells, or CSCs, and tumor bulk. It is developing two clinical-stage product candidates, SL-401 and SL-701. SL-401 is a targeted therapy directed to the interleukin-3 receptor, or IL-3R, present on CSCs and tumor bulk. SL-401 has demonstrated single-agent activity, including durable complete responses, or CRs, in investigator sponsored Phase 1/2 trials in several indications including blastic plasmacytoid dendritic cell neoplasm, or BPDCN, and relapsed or refractory acute myeloid leukemia, or AML. SL-701 is a subcutaneously-a...moredministered therapeutic cancer vaccine comprised of multiple synthetic peptides. The vaccine has demonstrated single-agent activity, including durable CRs and partial responses, or PRs, in investigator sponsored Phase 1/2 trials in advanced adult and pediatric brain cancers. In addition, Company has built a preclinical pipeline which includes next generation IL-3R-targeted compounds SL-501 and SL-101 discovery platform, and an intellectual property portfolio including some of the earliest patents in the CSC area. Some of its competitors include Cyclacel Pharmaceuticals, Inc., Sunesis Pharmaceuticals Inc., Clavis Pharma ASA, Ambit Biosciences Corporation, Celgene Corporation, Merck & Co., Inc., Eisai Co., Inc. and Roche Holding AG. Government authorities in the United States, at the federal, state and local level, and in other countries extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing and export and import of products such as those it is developing.lessless

                      Key People

                      Dr. Ivan Bergstein

                      CEO/Chairman of the Board/Director/Founder/President

                      Dr. Eric K. Rowinsky,M.D.

                      Chief Medical Officer/Executive VP/Other Corporate Officer

                      Mr. David G. Gionco

                      Chief Accounting Officer/Vice President, Divisional

                      Eric L. Dobmeier

                      Director

                      Ron Bentsur

                      Director

                      • Stemline Therapeutics Inc

                      • 750 Lexington Avenue

                      • New York, NY 10022

                      • USA.Map

                      • Phone: +1 646 502-2311

                      • Fax: +1 646 389-0968

                      • stemline.com

                      Incorporated

                      2003

                      Employees

                      20

                      Send Feedback

                      We appreciate your input!

                      • I'm having trouble signing into my Microsoft account

                      • I’m having problems with the services stripe (Mail, Facebook, etc.)

                      • There is an issue with my weather information

                      • I see an error in the content

                      • Other

                      Please give an overall site rating: